1758 related articles for article (PubMed ID: 23683257)
21. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
22. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
23. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
Asami K
Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
[TBL] [Abstract][Full Text] [Related]
24. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
25. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl W; Tufman A; Huber RM
Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
27. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
29. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
30. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Lau SC; Chooback N; Ho C; Melosky B
Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
[TBL] [Abstract][Full Text] [Related]
32. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
33. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
[TBL] [Abstract][Full Text] [Related]
34. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q; Baijal S; Taniere P; O'Sullivan B; Evans M; Middleton G
Pathol Oncol Res; 2018 Oct; 24(4):723-731. PubMed ID: 29270776
[TBL] [Abstract][Full Text] [Related]
35. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
36. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
39. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
40. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
Abdallah SM; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]